Cowen Healthcare Investments
VC Fund
New York, United States
Cowen Healthcare Investments is a VC fund in New York focused on Biotechnology and Health Care. Cowen Healthcare Investments invests fiduciary capital in healthcare companies across the biopharma, diagnostics and digital health sectors.
- Total investments:
- 68
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cowen Healthcare Investments invests in
Stages Cowen Healthcare Investments invests in
Countries Cowen Healthcare Investments invests in
Investment Focus
Industry
- Biotechnology 44 (65%)
- Health Care 28 (41%)
- Therapeutics 21 (31%)
- Medical 18 (26%)
- Pharmaceutical 14 (21%)
Stage
- Series B 26 (38%)
- Series C 17 (25%)
- Series A 8 (12%)
- Post-IPO Equity 6 (9%)
- Venture - Series Unknown 5 (7%)
Country
- United States 39 (57%)
- United Kingdom 5 (7%)
- Switzerland 3 (4%)
- Canada 1 (1%)
- The Netherlands 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nuvig Therapeutics
|
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases. | $161M / Series B / Dec 05, 2024 | |
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $106.6M / Series C / May 13, 2024 | |
Aro Biotherapeutics
|
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action.Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids. | $41.5M / Series B / Nov 28, 2023 | |
MBrace Therapeutics
|
MBrace Therapeutics is a privately held biopharmaceutical business dedicated to improving cancer patients' quality of life by developing antibody-drug conjugates (ADCs) against novel oncology targets. | $85M / Series B / Nov 14, 2023 | |
MapLight Therapeutics
|
MapLight Therapeutics offers a platform designed to discover and develop therapeutics for brain disorders. It combines single-cell transcriptomics and optogenetics to identify novel drug targets and develop effective therapies for brain disorders. | $225M / Series C / Oct 30, 2023 | |
Tourmaline Bio
|
Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients and prevent immune diseases. | $75M / Post-IPO Equity / Oct 19, 2023 | |
Star Therapeutics
|
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $90M / Series C / Sep 05, 2023 | |
TORL BioTherapeutics
|
TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs. | $158M / Series B / Apr 13, 2023 | |
Orchard Therapeutics
|
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston. | $34M / Post-IPO Equity / Mar 06, 2023 | |
|
Tourmaline Bio
|
Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients and prevent immune diseases. | $112M / Series A / Jan 01, 2023 | |
| See all 68 investments → | |||
Co-Investors
OrbiMed
22 deals together
Redmile Group
12 deals together
Surveyor Capital
12 deals together
RA Capital Management
11 deals together
Westlake Village BioPartners
10 deals together
Eventide
9 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cowen Healthcare Investments invest in?
Cowen Healthcare Investments invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 68 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cowen Healthcare Investments last invest?
The most recent investment recorded for Cowen Healthcare Investments closed in Dec 2024. Shizune tracks 68 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
